| HOME >> BIOLOGY >> TECHNOLOGY |
-Abstract describes six-gene biomarker panel for assessment of current risk
for colorectal cancer-
TORONTO, March 17 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing molecular diagnostic tests derived from a simple blood sample for the early detection of diseases and personalized health management, today announced that its abstract describing the performance of the Company's six-gene biomarker panel for the assessment of a person's current risk for colorectal cancer from a blood sample, has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008 in San Diego, California. The abstract is entitled "Stratification of colorectal cancer probability using six genes from whole blood."
"This six gene biomarker set will form the basis of a laboratory developed test (LDT) version of ColonSentry(TM), which we expect to launch in the third quarter of 2008 through our in-house clinical reference lab located in the Toronto-area," said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. "We are pleased that AACR has chosen to accept our abstract given the limited number of late-breaking submissions that are accepted and believe that this acceptance also represents further peer-reviewed validation of our proprietary Sentinel Principle technology."
The following GeneNews abstract will be presented:
Abstract Number LB-214:
"Stratification of colorectal cancer probability using six genes from whole blood." Clinical Research 2, Poster Section 19, Tuesday, April 15, 2008, 8:00 AM
About GeneNews
--------------
GeneNews is focused on the application of functional genomics to enable
early diagnosis and personalized therapeutic intervention based on
disease-specific biomarkers. The Company has developed a novel approach,
the Sentinel Principle(TM), to detect and stage v
'/>"/>
| SOURCE GeneNews Limited Copyright©2008 PR Newswire. All rights reserved |